Sign Up for Pfizer Chantix Class Action Lawsuit
Pfizer Chantix class action lawsuit is currently open:
Those who meet eligibility criteria should apply before the deadline September 12, 2026. Pfizer allegedly sold Chantix contaminated with a probable human carcinogen while misrepresenting its manufacturing standards.
Pfizer Chantix Class Action Lawsuit
A class action lawsuit has been filed against Pfizer Inc. over its blockbuster smoking-cessation drug Chantix (varenicline). Plaintiffs allege that Pfizer failed to follow current good manufacturing practices and that Chantix pills became contaminated with N-nitroso-varenicline, a nitrosamine impurity described in court filings as a genotoxic, probable human carcinogen. Pfizer halted distribution and recalled Chantix lots in 2021 after the contamination came to light, and dozens of consumer suits were consolidated into a multidistrict litigation in the U.S. District Court for the Southern District of New York before Judge Katherine Polk Failla (case number 22-MD-3050).
The Chantix class action case centered on claims that Pfizer misrepresented its adherence to good manufacturing practices while selling a premium-priced branded drug. The consolidated Chantix lawsuit details included claims for breach of warranty, fraud, negligent misrepresentation, violations of state consumer protection laws, and unjust enrichment, though the court later narrowed the case to the consumer protection and related claims.
Court-appointed class counsel from Honik LLC, Levin Sedran & Berman LLP, and Scott+Scott Attorneys at Law LLP reviewed more than 250,000 documents totaling roughly 2.11 million pages before reaching the settlement. Pfizer denies any wrongdoing and settled to avoid the cost and uncertainty of continued litigation over the Chantix legal claims.
Pfizer Chantix Class Action Settlement - $44,000,000
Pfizer has agreed to pay $44,000,000 to resolve the Chantix class action settlement, and the court granted preliminary approval on June 1, 2026. The settlement fund is non-reversionary, meaning none of the $44 million goes back to Pfizer. This Chantix settlement update covers everyone who paid any amount of money for retail purchases of Chantix in the United States and its territories between September 29, 2015 and September 17, 2021 — both individual consumers and third-party payors such as insurers.
After attorneys fees, litigation expenses, administration costs, and service awards are deducted, up to 20 percent of the available settlement fund is set aside for individual consumers, with the remainder going to third-party payors. That split reflects class counsel's best estimate of how much of every Chantix purchase was paid by patients versus their insurers.
Chantix settlement eligibility does not require any receipts or paperwork up front, and claims can be submitted online in minutes. The deadline to file a claim is September 12, 2026, and the final approval hearing is scheduled for October 13, 2026.
Deadline for filing a claim: September 12, 2026
Chantix Class Action Payout: $150
Each consumer with an approved claim will receive a pro rata share of the consumer portion of the fund based on the total out-of-pocket amount they paid for Chantix — copays, coinsurance, and deductibles all count. No one's payment can exceed what they actually spent, so the Chantix settlement amount per person will vary: someone who paid a handful of $25 copays will receive less than someone who paid hundreds of dollars cash for the branded drug.
If you are wondering how much you will get from the Chantix lawsuit, the honest answer is that it depends on how much you paid and how many people file. If money is left over after the first round of checks, it will be redistributed to claimants who cashed their payments rather than reverting to Pfizer.
Payments will be sent digitally by email by default, with alternative payment options available on request. Checks are expected to go out after the final approval hearing on October 13, 2026, allowing time for any appeals and claim processing. If your payment does not arrive, you can call the settlement administrator at 1-877-354-3912.
Chantix Class Action Eligibility
You qualify for the Chantix class action settlement if you paid any amount of money for retail purchases of Chantix in the United States or its territories between September 29, 2015 and September 17, 2021. Insurance users qualify too — what matters is that you personally paid something out of pocket, whether that was a copay, coinsurance, a deductible, or the full cash price.
A few groups are excluded: officers, directors, managers, and employees of Pfizer; government agencies and governmental actors, including state attorney general offices; anyone whose only Chantix purchases fell outside the September 29, 2015 to September 17, 2021 window; anyone who bought Chantix for resale; and anyone who previously opted out of this case. Notably, only branded Chantix counts — purchases of generic varenicline are not covered.
Chantix class action claimants do not need receipts to file. The claim form asks how many prescriptions you purchased, your total out-of-pocket spending, and whether insurance covered part of the cost. Claims must be filed by September 12, 2026.
Chantix Class Action Claim Form
1
2
3
FAQ
It is a nitrosamine impurity found in Chantix pills, described in court filings as a genotoxic, probable human carcinogen. Its discovery led Pfizer to halt distribution and recall Chantix lots in 2021.
No. You just report how many prescriptions you bought and your total out-of-pocket cost. The settlement administrator may later request backup like a pharmacy record, insurance explanation of benefits, or prescription records.
No. Only retail purchases of brand-name Chantix, made by Pfizer, are covered. Generic varenicline came to market around the time of the 2021 recall and is not part of this settlement.
Yes. Copays, coinsurance, and deductibles all count as out-of-pocket spending. The claim form asks for your insurer's name and policy number if insurance covered part of your purchases.
The rest goes to third-party payors like health plans, which typically paid the bulk of each prescription's price. The 20% cap reflects class counsel's estimate of the share consumers actually paid at the register.
Payments are sent digitally to your email address by default. You can affirmatively choose an alternative payment method when you file, so keep your email and phone number current with the administrator.
Nothing goes back to Pfizer — the $44 million fund is non-reversionary. Leftover funds after the first distribution are redistributed pro rata to class members who claimed their payments.
Class counsel may request up to one-third of the fund plus expenses, subject to court approval. Named consumer plaintiffs will seek $5,000 service awards each; third-party payor plaintiffs will seek $15,000 each.
No. Pfizer denies any wrongdoing and maintains it did nothing unlawful. It settled to avoid the uncertainty and expense of continued litigation after years of discovery in the multidistrict case.
No. Each consumer's recovery is capped at their documented out-of-pocket spending. If total claims exceed the consumer allocation, every payment is reduced proportionally based on dollars paid.